CD8A and neoplasm: Whereas blocking each of the PD-1/PD-L1 or TIGIT pathways does not remarkably impede the growth of CT26 tumors, a dual blockade synergizes to increase the proliferation and function of antitumor CD8+ T cells, which results in protective memory T cells, complete tumor rejection, and overall prolonged survival (126, 131).